Navigation Links
ProteoTech to Present at 9th International Conference for Alzheimer's and Parkinson's Disease - Prague, Czech Republic, March 11-15, 2009
Date:3/9/2009

KIRKLAND, Wash., March 9 /PRNewswire/ -- ProteoTech Inc. announced today that both Dr. Alan D. Snow, Chairman, President & CSO, and Dr. Luke Esposito, Director of In Vitro Screening, will present at the 9th International Conference for Alzheimer's and Parkinson's Diseases, to be held in Prague, Czech Republic, March 11-15, 2009. On Sunday March 15, Dr. Alan D. Snow will give an oral presentation discussing promising results pertaining to ProteoTech's current Phase 1A human clinical trial with the small molecule Exebryl-1 for the treatment of mild-to-moderate Alzheimer's disease. Dr. Snow's talk is entitled: "Exebryl-1: A Novel Small Molecule Currently in Human Clinical Trials as a Disease-Modifying Drug for the Treatment of Alzheimer's Disease."

(Logo: http://www.newscom.com/cgi-bin/prnh/20090226/SF76109LOGO)

Dr. Luke Esposito on Saturday March 14-Sunday March 15 will present during the "Synucleinopathies" poster session. Dr. Esposito's presentation is entitled: "Synuclere(TM): Development of a Novel Small Molecule that Effectively Reduces Alpha-Synuclein Aggregation and Improves Motor Dysfunction". Synuclere(TM) is a novel small molecule developed by ProteoTech that looks promising as a future disease-modifying treatment for Parkinson's disease and related disorders. ProteoTech's work in Parkinson's disease was partially funded by a LEAPS award from The Michael J. Fox Foundation for Parkinson's Research.

About ProteoTech: ProteoTech is a private drug development Company founded in 1996 that is a world-leader in therapeutics targeting amyloid diseases. With over 175 patents in its intellectual property estate, ProteoTech is in human clinical trials for its orally active small molecule drug Exebryl-1 for the treatment of mild-to-moderate Alzheimer's disease. The Company is in late-stage
'/>"/>

SOURCE ProteoTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. ProteoTech to Present at Rodman & Renshaws 10th Annual Healthcare Conference
2. ProteoTech Receives Funding From The Michael J. Fox Foundation for Parkinsons Disease Research to Develop Tools for Imaging Alpha-Synuclein Aggregation in Living Parkinsons Brain
3. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
4. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
5. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
6. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
7. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
8. AtriCure to Present at Roth Capital Partners 2007 New York Conference
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. MDS to Present at Thomas Weisel Partners Healthcare Conference
11. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... (PRWEB) February 28, 2015 In recent years ... number of practicing physicians as a way for them to ... education regarding Cannabis as medicine. Since the FDA still lists ... few resources available to licensed physicians that can help ... patient. Dr. Deborah Malka in Santa Cruz, CA is ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 With their ... Fitness has added an additional exercise to their already ... oblique exercise is most commonly known as, is often ... “Rope Pulls” are executed in a relatively safe manner ... and strength levels. The full description of “Rope Pulls” ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Mew and ... announced that they now provide business consulting services in ... as corporate tax planning and succession planning. Company finances ... to experienced professionals. On top of this, complex Canadian ... handle corporate accounting. As a result, Mew and Company ...
(Date:2/28/2015)... 28, 2015 For those people who ... the Mesothelioma Applied Research Foundation (Meso Foundation) ... March 3, starting at 9:30 AM. , The live ... The broadcast can be accessed through any browser on ... , The Symposium is a unique event that covers ...
(Date:2/28/2015)... Pismo Beach, CA (PRWEB) February 28, 2015 ... the needs of Central Coast area residents, recently announced ... Whitening System. It’s a treatment option for new ... patients kick off 2015 with a bright, white smile, ... the discounted price of $299, marked down from the ...
Breaking Medicine News(10 mins):Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2
... Cardiva Medical, Inc. announced today that it has received ... for its latest technology, the Cardiva Catalyst III, which ... in the market. Built upon its predecessor, the ... which neutralizes heparin in the tissue adjacent to the ...
... 19 Nuvilex, Inc. (OTC Bulletin Board: NVLX), an ... aesthetics, dermatology, environmental and nutraceutical products, today announced that ... Tuesday, June 2, 2009 at 4:30 PM Eastern Time. ... (U.S.) and 1-201-689-8471 (international). The call will also ...
... (www.meettheburns.com) targets first time athlete,s foot sufferers and ... Schering-Plough Corporation (NYSE: SGP ) ... antifungal spray for the treatment of athlete,s foot. ... spray and deodorant powder spray.(Photo: http://www.newscom.com/cgi-bin/prnh/20090519/NY19030 ...
... profile "New Strategies for Optimizing CHO Performance" inside the BIO Process ... ... Fort Collins, CO (PRWEB) May 19, 2009 -- Amidst ... International Convention will be InVitria, a cell culture media supplement company ...
... patient with help from GI specialists, GI Monitor, an ... (IBD) Crohn,s and Ulcerative Colitis to track their symptoms ... N.J., May 19 WellApps, Inc. launched an iPhone ... Colitis provide accurate symptom data to their doctors for ...
... May 19 Regulatory processes differ across continents, ... pressing need to integrate the regulatory environment of ... regulations impact drug launches as less price controlled ... in regulated markets. The pharmaceutical industry, along with ...
Cached Medicine News:Health News:Cardiva Medical, Inc. Receives FDA Clearance for the Catalyst(TM)III System, First in Class Drug Coated Vessel Closure Device 2Health News:Cardiva Medical, Inc. Receives FDA Clearance for the Catalyst(TM)III System, First in Class Drug Coated Vessel Closure Device 3Health News:Nuvilex, Inc. Announces Monthly Investor Conference Call 2Health News:Video: Schering-Plough Introduces TINACTIN(R) CHILL, a Line of Antifungal Products Geared Specifically to Young Males 2Health News:InVitria to Present at BIO 2009 International Convention in Atlanta 2Health News:IBD Patient Launches iPhone Application to Help Doctors Treat Crohn's and Ulcerative Colitis 2Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 2Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 3Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 4
(Date:2/27/2015)... 2015   Synageva BioPharma Corp. (Synageva) ... developing therapeutic products for rare diseases, joins the ... Organisation for Rare Diseases™ (EURORDIS™), The Global Genes ... Rare Disease Day. On the last ... and other participants conduct special events to raise ...
(Date:2/27/2015)... SOUTH PLAINFIELD, N.J., Feb. 27, 2015  PTC Therapeutics, ... corporate update and reported financial results for the fourth ... "2014 was a transformative year for PTC. ... on delivering and developing RNA-targeted therapies in the rare ... Officer, PTC Therapeutics, Inc. "We are proud to bring ...
(Date:2/27/2015)... -- Uroplasty, Inc. (NASDAQ: UPI ), a medical device ... to treat voiding dysfunctions, today announced that it will ... March 10, 2015. Rob Kill , President and ... will present at 4:00 p.m. Pacific Time and meet ... the Ritz Carlton in Laguna Niguel, CA. ...
Breaking Medicine Technology:Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Uroplasty to Participate in the 27th Annual ROTH Conference 2
... to Treat Renal Artery Obstructions and Lower Blood ... Pressure in Patients Not Responding to Medication, ABBOTT ... enrollment of the first patient in HERCULES (Herculink,Elite Cobalt ... U.S. clinical trial designed to evaluate the safety and,effectiveness ...
... Pivotal Phase -, WALTHAM, Mass., Sept. 25 ... clinical trial strategy for,the SEPET(TM) Liver Assist Device including ... and Drug Administration (FDA).,In a meeting held between Arbios ... the FDA indicated that, pending receipt of a final,report, ...
Cached Medicine Technology:Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis 2Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis 3Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial 2Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial 3Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial 4
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
... incorporate a layered design unique in the ... to prevent stray electrosurgical burns along the ... failure or capacitive coupling; a well-documented patient ... all AEM Instruments provides a neutral return ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
Medicine Products: